**Core tip:** The number of the pediatric Middle East respiratory syndrome-coronavirus (MERS-CoV) is low and the exact reason for the low prevalence is not known. A total of 31 pediatric MERS-CoV cases were reported since June 2012. Of all the cases 13 (42%) were asymptomatic and the male to female ratio was 1.7:1. The mean age of patients was 9.8 ± 5.4 years.The most common source of infection was household contact followed by infection within a health care facility. Using real time reverse transcriptase polymerase chain reaction of pediatric patients revealed that 9 out of 552 (1.6%) was positive in the Kingdom of Saudi Arabia.

INTRODUCTION
============

Middle East respiratory syndrome-coronavirus (MERS-CoV) was first isolated in 2012 from a patient in the Kingdom of Saudi Arabia (KSA)\[[@B1]\]. As more cases were reported, the case fatality rate changed to 40% from 60%\[[@B2]-[@B5]\]. In addition, initially there was a predominance of males; later this ratio decreased\[[@B2],[@B6]\]. MERS-CoV is characterized by three different patterns of disease: Sporadic cases, intra-familial transmission\[[@B7]-[@B9]\] and health care associated infection\[[@B2],[@B3],[@B10]-[@B16]\]. Despite the increased number overtime and the multiple health care associated outbreaks\[[@B17]\], the number of pediatric cases remained low during the study period\[[@B18]\]. The initial description of 47 cases included only a 14-year-old child\[[@B4]\]. The first pediatric case was a 2-year-old child reported from Jeddah, KSA on June 28, 2013\[[@B19]\]. Later an additional three asymptomatic children were reported\[[@B4]\]. The largest report of childhood MERS-CoV cases included eleven, of which two patients were symptomatic and nine were asymptomatic\[[@B18]\]. The exact reason for this low prevalence of the disease in children is not known. In this study, we summarize the reported MERS-CoV cases and the associated clinical presentation and the outcome.

MATERIALS AND METHODS
=====================

We searched the Saudi Ministry of Health website\[[@B20]\], the World Health Organization website\[[@B21]\], the Flutracker website\[[@B22]\], the medical literature and the retrieved published studies for any childhood MERS-CoV infections. We searched MEDLINE and PubMed for the keywords Middle East respiratory syndrome-coronavirus, MERS-CoV, in combination with pediatric, children, childhood, infancy and pregnancy from the initial discovery of the virus in June 2012 until April 19, 2016. The retrieved articles were also read to find other relevant articles.

Statistical analysis
--------------------

Relevant data were placed into an excel sheet and analyzed accordingly. Descriptive analytic statistics were used in the final analysis as deemed necessary, including mean and standard deviation when applicable and frequency. The statistical review of the study was performed by a biomedical statistician. Statistical review is performed before the submission of the manuscript.

RESULTS
=======

Summary of pediatric cases
--------------------------

From June 2012, to April 19, 2016, there were a total of 31 pediatric MERS-CoV cases as shown in Table [1](#T1){ref-type="table"}. Of all the cases, thirteen (13) or 42% were asymptomatic, and there were 17 males, 10 females and 4 unreported (a male to female ratio of 1.7:1). The mean age of patients was 9.8 + 5.4 (0.75-17) years. Twenty-five cases (80.6%) were reported from KSA; the other patients were in Jordan, United Arab Emirates and the Republic of Korea (Table [1](#T1){ref-type="table"}). The most common source of the infection was household contact (10 of 15 with reported source), and 5 patients acquired the infection within a health care facility. About one half of the cases were reported in 2014, and 29% were reported in 2013 and 22.6% in 2015 (Table [2](#T2){ref-type="table"}).

###### 

Summary of reported pediatric Middle East respiratory syndrome cases

  **Age**   **Gender**   **Country**   **Sample source**    **Year of reporting**   **Symptoms**                  **Co-morbidity**       **Signs**                           **Sample type**     **Viral load ct value**   **Imaging**                     **Intensive care**   **Death**   **Ref**.
  --------- ------------ ------------- -------------------- ----------------------- ----------------------------- ---------------------- ----------------------------------- ------------------- ------------------------- ------------------------------- -------------------- ----------- -------------------
  2         Male         KSA           Hospital inpatient   2013                    Fever, respiratory distress   Cystic fibrosis        Chest: Bilateral fine crepitation   NPS                 36                        Bilateral diffused infiltrate   \+                   Yes         \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  14        Female       KSA           Hospital inpatient   2013                    Fever                         Down's syndrome                                            NPS                 37                        Bilateral diffused infiltrate   No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  7         Female       KSA           Family contact       2013                    Asymptomatic                  None                   None                                N + T               37                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  15        Female       KSA           Family contact       2014                    Asymptomatic                  None                   None                                NPS                 35                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  14        Male         KSA           Family contact       2014                    Asymptomatic                  None                   None                                NPS                 34                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  12        Female       KSA           Family contact       2014                    Asymptomatic                  None                   None                                NPS                 35                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  16        male         KSA           Family contact       2013                    Asymptomatic                  None                   none                                NPS                 36                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  7         Female       KSA           Family contact       2014                    Asymptomatic                  None                   none                                NPS                 37                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  3         Female       KSA           Family contact       2013                    Asymptomatic                  None                   none                                NPS                 38                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  13        Female       KSA           Contact              2014                    Asymptomatic                  None                   none                                NPS                 34                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  14        Female       KSA           Family contact       2013                    Asymptomatic                  None                   none                                NPS                 36                        ND                              No                   No          \[[@B18]\]
                                                                                                                                                                                                                                                                                            
  0.75      Male         KSA           Not known            2014                    ICU                           Nephrotic syndrome     Respiratory distress                Tracheal aspirate   NA                        Diffuse bilateral haziness      Yes                  Yes         \[[@B35]\]
                                                                                                                                                                                                                                                                                            
  4         Male         KSA           NA                   2013                    Mild respiratory symptoms     None                   NA                                                      NA                        ND                              No                   No          \[[@B36]\]
                                                                                                                                                                                                                                                                                            
  8         Male         KSA           NA                   2013                    Mild respiratory symptoms     None                   NA                                                      NA                        ND                              NA                   No          \[[@B37]\]
                                                                                                                                                                                                                                                                                            
  17        NA           KSA           Contact              2014                    Asymptomatic                  NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  11        NA           KSA           Contact              2014                    Asymptomatic                  NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  16        NA           KSA           NA                   2014                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  13        M            KSA           NA                   2014                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  10        M            KSA           Hospital contact     2014                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  2         NA           KSA           NA                   2014                    Symptomatic                   Congenital anomalies   NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  11        M            KSA           Hospital contact     2014                    Symptomatic                   Brain tumor            NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  17        M            KSA           NA                   2014                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  16        M            South Korea   Hospital contact     2015                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  2         M            KSA           Hospital contact     2015                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  16        M            KSA           contact              2015                    Symptomatic                   NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  7         F            Jordan        Contact              2015                    Asymptomatic                  None                   NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  0.8       F            Jordan        Contact              2015                    Symptomatic                   None                   NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  14        M            KSA           Contact              2015                    Symptomatic                   None                   NA                                  NA                  NA                        NA                              NA                   NA          \[[@B20],[@B22]\]
                                                                                                                                                                                                                                                                                            
  4         M            UAE           NA                   2014                    NA                            NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  8         M            UAE           Family contact       2013                    NA                            NA                     NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]
                                                                                                                                                                                                                                                                                            
  11        M            UAE           Family contact       2015                    Asymptomatic                  None                   NA                                  NA                  NA                        NA                              NA                   NA          \[[@B22]\]

NPS: Nasopharyngeal swab; N + T: Nasal and tracheal aspirate; ND: Not done; KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates; ICU: Intensive care unit; NA: Not available.

###### 

Summary of the demographic characteristics of pediatric Middle East respiratory syndrome-coronavirus

                   **No**.         **%**
  ---------------- --------------- ------------
  Male:female      17:10 (1.7:1)   63 *vs* 37
  Saudi            20              83.3
  City                             
  Jeddah           7               29.2
  Riyadh           7               29.2
  Hafr al-Batin    3               12.5
  Symptomatic      12              50.0
  Death            8               33.3
  Year of report                   
  2013             9               29
  2014             15              48.4
  2015             7               22.6

Screening of pediatric patients for MERS-CoV
--------------------------------------------

Screening of pediatric patients for MERS-CoV infection using real time reverse transcriptase polymerase chain reaction showed that only 9 out of 552 (1.6%) were positive in KSA\[[@B23]\]. However, serologic testing of pediatric patients admitted with lower respiratory tract infection in Jordan and Saudi Arabia revealed no positive tests\[[@B24],[@B25]\] (Table [3](#T3){ref-type="table"}).

###### 

Summary of different studies examining Middle East respiratory syndrome-coronavirus infection in children

  **Country**   **Testing method**                **Population**                                                                    **Positive *n* (%)**   **Yr**              **Ref**.
  ------------- --------------------------------- --------------------------------------------------------------------------------- ---------------------- ------------------- ------------
  KSA           rRT-PCR                           Screening of children                                                             9/552 (1.6)                                \[[@B23]\]
  KSA           Neutralizing antibodies testing   Serum samples from children hospitalized for lower respiratory tract infections   0/158 (0)              May 2010-May 2011   \[[@B25]\]
  Jordan        rRT-PCR                           Hospitalized children \< 2 yr of age                                              0/2427 (0)                                 \[[@B24]\]

rRT-PCR: Real time reverse transcriptase polymerase chain reaction; KSA: Kingdom of Saudi Arabia.

Pregnancy associated MERS-COV
-----------------------------

The effect of MERS-CoV infection on the fetus was described in eight cases\[[@B26]-[@B29]\] as summarized in Table [4](#T4){ref-type="table"}. The mean age of the mothers was 32.25 + 3.4 years, and the mean gestational age was 28.4 + 6.3 wk. Death of the fetus was observed in 3 (37.5%) of the 8 fetuses.

###### 

Summary of pregnancy associated Middle East respiratory syndrome-coronavirus infection

  **Age of the patient (yr)**   **Gestational age**   **Fetal outcome**   **Diagnostic test**   **Country**            **Ref**.
  ----------------------------- --------------------- ------------------- --------------------- ---------------------- ------------
  39                            5 mo                  Still birth         Antibody by EIA       Jordan                 \[[@B26]\]
  33                            32 wk                 Healthy infant      PCR                   Saudi Arabia           \[[@B27]\]
  32                            32 wk                 Healthy             PCR                   United Arab Emirates   \[[@B28]\]
  34                            34 wk                 Died                PCR                   Saudi Arabia           \[[@B29]\]
  32                            38 wk                 Survived            PCR                   Saudi Arabia           \[[@B29]\]
  31                            24 wk                 Died                PCR                   Saudi Arabia           \[[@B29]\]
  27                            22 wk                 Survived            PCR                   Saudi Arabia           \[[@B29]\]
  30                            23 wk                 Survived            PCR                   Saudi Arabia           \[[@B29]\]

PCR: Polymerase chain reaction; EIA: Enzyme immunoassay.

DISCUSSION
==========

Despite the total number of MERS cases increasing, especially in KSA, the number of pediatric cases remained low during the study period. Initially, the testing in KSA was directed towards hospitalized patients with severe pneumonia. In 2015, the Saudi Ministry of Health added a specific case definition for MERS-CoV infection in children\[[@B30]\]. The definition includes those ≤ 14 years, meets the adult case definition and has either a history of exposure to a confirmed or suspected MERS-CoV in the proceeding 14 d or a history of contact with camels or camel products in the proceeding 14 d\[[@B30]\]. The case definition also includes children with unexplained severe pneumonia\[[@B30]\]. The 2015 change in the case definition does not account for the low rate of childhood MERS-CoV infection as 33% of the cases were reported in 2014 before the case definition was changed. One of the reasons for an increased number of cases in 2014 during the Jeddah outbreak was increased testing of asymptomatic and mildly symptomatic patients\[[@B11]\].

The pattern of MERS-CoV pediatric cases was similar to the 2003 SARS outbreak. Children were less affected than adults and children less than 2 years of age had milder disease\[[@B31]\]. In the largest screening of contacts, the rate of MERS-CoV positive children (1.6%, 9/616) compared to 2.2% (99/4440) in adults (*P* = 0.23)\[[@B23]\]. Thus, in this study utilizing MERS-CoV PCR the positivity rate did not differ in children and adults.

In adults with MERS-CoV infections, three patterns of transmissions were observed: Sporadic (primary) cases presumed to be due to animal exposure (mainly camels), household contacts or health care associated infections\[[@B32]\]. In KSA, the majority (45%) of cases were health care-associated infections, 38% were primary cases, and 13% were household contacts\[[@B32]\]. In contrast, in the majority of pediatric cases that reported source of acquisition (66.7% of the 15 with reported source), the disease was acquired through household contact. This pattern indicates a low exposure of children to animals and a higher rate of health care associated infections in adult wards. The male to female ratio (2.8:1 and 3.3:1) was initially high\[[@B3],[@B4]\]. This apparent male predominance could be explained by the nature of hospital outbreaks\[[@B2]\]. Eventually the male to female ratio was reduced to 1.3:1 to 1.8:1\[[@B5],[@B6]\]. Consistent with these studies, the male to female ratio in children with MERS-CoV was 1.7:1 and may indicate similar exposure of children to index cases in the household settings and differential host factors.

Possible explanations for the lower number of pediatric cases compared to adults include differential testing of adult patients and milder diseases in children; although, serologic testing of pediatric patients in KSA and Jordan did not reveal any positive cases\[[@B24],[@B25]\]. In the largest sero-epidemiologic survey in KSA, the study did not include children and thus it is difficult to establish the rate of sero-positivity in children\[[@B31]\].

The MERS-CoV infection rate in children remains low and possible explanations include: A milder disease in children, asymptomatic infection, or the presence of yet to be identified factors. The development of a shorter duration of MERS in children is another possible explanation. If this is the case, it may limit the development of a positive serology. In one study, delayed antibody responses as measured with the neutralization test was associated with severe diseases\[[@B33]\]. The longevity of antibodies in MERS-CoV cases might be limited as was the case with SARS\[[@B33],[@B34]\]. The only study of serology among children was done among hospitalized pediatric cases who presented with lower respiratory tract infections\[[@B25]\]. There is no systematic screening of exposed children using serologic testing; this limited the interpretation of available serologic studies.

Little data also exist regarding the effect and the likelihood of MERS-CoV in pregnancy. Eight cases were reported\[[@B26],[@B27],[@B29]\]. The outcome was favorable in the majority of cases. The exact prevalence of MERS-CoV antibodies and exposure of pregnant women to MERS-CoV is not known.

In conclusion, the number of MERS-CoV infections in pediatric patients remains low. Possible explanations include low exposure, presence of asymptomatic, mildly symptomatic patients or the presence of yet to be identified factors. The immune system predisposing to severe disease and to fatal outcome remains unknown. An exploration of the virus-host interaction may add to the understanding of the low prevalence in this age group.
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Middle East respiratory syndrome-coronavirus (MERS-CoV) was first isolated in 2012 from a patient in the Kingdom of Saudi Arabia (KSA). Despite the increased number of MERS-CoV cases overtime, the number of pediatric cases remained low. The exact reason for this low prevalence of the disease in children is not known. The aim of this study is to summarize the reported MERS-CoV cases and the associated clinical presentation and the outcome.

Research frontiers
------------------

The first pediatric case was a two-year-old child reported from Jeddah, KSA on June 28, 2013. Later an additional three asymptomatic children were reported. The largest report of childhood MERS-CoV cases included eleven, including nine asymptomatic cases.

Innovations and breakthroughs
-----------------------------

The number of MERS-CoV infections in pediatric patients remains low. Possible explanations include low exposure, presence of asymptomatic, mildly symptomatic patients or the presence of yet to be identified factors. The immune system predisposing to severe disease and to fatal outcome remains unknown. An exploration of the virus-host interaction may add to the understanding of the low prevalence in this age group.

Applications
------------

Despite the low number of pediatric MERS-CoV cases, it is important to continue to monitor the development of this disease in this age group and to understand the risk factors.

Terminology
-----------

MERS-CoV is a new emerging virus that was first isolated in 2012.
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This complication of all known pediatric cases is a useful contribution to the medical literature, and knowing it is possible but rare is important.
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